EP1562606A4 - Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes - Google Patents

Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes

Info

Publication number
EP1562606A4
EP1562606A4 EP03768685A EP03768685A EP1562606A4 EP 1562606 A4 EP1562606 A4 EP 1562606A4 EP 03768685 A EP03768685 A EP 03768685A EP 03768685 A EP03768685 A EP 03768685A EP 1562606 A4 EP1562606 A4 EP 1562606A4
Authority
EP
European Patent Office
Prior art keywords
vitamin
compounds
treatment
methods
myelodysplastic syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03768685A
Other languages
German (de)
French (fr)
Other versions
EP1562606A2 (en
Inventor
Martha J Whitehouse
John G Curd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacea Inc
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of EP1562606A2 publication Critical patent/EP1562606A2/en
Publication of EP1562606A4 publication Critical patent/EP1562606A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03768685A 2002-11-06 2003-11-06 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes Withdrawn EP1562606A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42454602P 2002-11-06 2002-11-06
US424546P 2002-11-06
PCT/US2003/035244 WO2004043360A2 (en) 2002-11-06 2003-11-06 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
EP1562606A2 EP1562606A2 (en) 2005-08-17
EP1562606A4 true EP1562606A4 (en) 2006-05-24

Family

ID=32312829

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03768685A Withdrawn EP1562606A4 (en) 2002-11-06 2003-11-06 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes

Country Status (8)

Country Link
EP (1) EP1562606A4 (en)
JP (1) JP2006508125A (en)
KR (1) KR20050086545A (en)
CN (1) CN100386083C (en)
AU (1) AU2003291294A1 (en)
CA (1) CA2505373A1 (en)
MX (1) MXPA05004985A (en)
WO (1) WO2004043360A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
EP1631297A4 (en) * 2003-06-11 2007-09-05 Novacea Inc Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2005117901A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Oral formulations of paricalcitol
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
CA2981549A1 (en) * 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN103142478B (en) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 Calcitriol emulsion and preparation method thereof
CN109864992B (en) * 2017-12-01 2021-07-27 暨南大学 Vitamin D3 or its active form 1 alpha, 25(OH)2D3Application in inhibiting PD-1 expression
CN111228301A (en) * 2020-01-14 2020-06-05 哈尔滨医科大学 Compound preparation for treating angiogenesis-mediated diseases and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049870A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
WO2004082631A2 (en) * 2003-03-18 2004-09-30 Bonecare International, Inc. METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049870A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
WO2004082631A2 (en) * 2003-03-18 2004-09-30 Bonecare International, Inc. METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMAI Y ET AL: "Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3.", CONTRIBUTIONS TO NEPHROLOGY. 1991, vol. 91, 1991, pages 95 - 101, XP009058493, ISSN: 0302-5144 *
MELLIBOVSKY LEONARDO ET AL: "Vitamin D treatment in myelodysplastic syndromes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 100, no. 3, 1 March 1998 (1998-03-01), pages 516 - 520, XP002358724, ISSN: 0007-1048 *
PAKKALA S ET AL T ET AL: "EB1089, a vitamin D analog in MDS and AML", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), & 39TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CALIFORNIA, USA; DECEMBER 5-9, 1997, pages 508A, XP009058524, ISSN: 0006-4971 *
TAKAHASHI T ET AL: "[Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders]", [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY. JAN 1989, vol. 30, no. 1, January 1989 (1989-01-01), pages 1 - 10, XP009058492, ISSN: 0485-1439 *

Also Published As

Publication number Publication date
MXPA05004985A (en) 2005-08-02
KR20050086545A (en) 2005-08-30
EP1562606A2 (en) 2005-08-17
CA2505373A1 (en) 2004-05-27
CN100386083C (en) 2008-05-07
AU2003291294A1 (en) 2004-06-03
WO2004043360A2 (en) 2004-05-27
JP2006508125A (en) 2006-03-09
WO2004043360A3 (en) 2004-10-14
CN1732009A (en) 2006-02-08

Similar Documents

Publication Publication Date Title
GB0206033D0 (en) Compounds useful in therapy
EP1689485A4 (en) Cardioelectromagnetic treatment
PT1583542E (en) Compositions and methods for combination antiviral therapy
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
TW595562U (en) Casket
EP1682136A4 (en) Therapeutic compounds and uses thereof
AU2003212634A8 (en) Compounds useful in the treatment of cancer
HK1078784A1 (en) Therapeutic treatment
EP1677816A4 (en) Therapeutic method
GB0312407D0 (en) Treatment
HK1060840A1 (en) Massager
GB0223367D0 (en) Therapeutic treatment
GB0329661D0 (en) Hyperbaric treatment device
GB0223570D0 (en) Surface treatment
EP1562606A4 (en) Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes
GB0308382D0 (en) Therapeutic methods and means
AU2003226725A8 (en) Pyrazolopyrimidine derivatives
GB0210464D0 (en) Therapeutic treatment
GB0329693D0 (en) Compounds useful in therapy
EP1569928A4 (en) Therapeutic compounds and methods
GB0219104D0 (en) Trouser-type massager
TW561896U (en) Phototherapy apparatus
AU2003231937A8 (en) Therapeutic methods
GB0312122D0 (en) Therapeutic method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050525

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/00 20060101ALI20051216BHEP

Ipc: A61K 31/59 20060101AFI20050610BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060412

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081860

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVACEA, INC.

17Q First examination report despatched

Effective date: 20070720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081860

Country of ref document: HK